<i>Salmonella</i>
            : from Pathogenesis to Therapeutics

Boyle, Erin C.; Bishop, Jennifer; Grassl, Guntram A.; Finlay, B. Brett

doi:10.1128/jb.01730-06

Cited by 131 publications

(108 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, the successes of clinical trials performed on the △aroC/△ssaV mutant to individuals in developing countries is a significant challenge. The new trials testing this vaccine strain in adults and children from developing countries are under way, and if successful, it could be the first single-dose oral vaccine for typhoid fever available worldwide (56).…”

Section: Therapeutic Measures To Salmonella Typhi Infections and Thementioning

confidence: 99%

Salmonella Typhi: from a Human Pathogen to a Vaccine Vector

2008

View full text Add to dashboard Cite

Salmonella (S.) typhi is an important intracellular pathogen. Among the more than 2,300 closely-related Salmonella serovars bacteria recognized, S. typhi is the only one that is pathogenic exclusively for humans, in whom it causes typhoid or enteric fever. The pathogen has been around for many years and many studies have been done in an effort to combat it. Molecular and biologic features of S. typhi and host factors and immune responses involved in Salmonella invasion have been extensively studies. Vaccines that have been developed most notably are Vi polysaccharide and Ty21a. However, as the results show, there is still a long way to go. It is also shown that multi-drug resistance has occurred to the few available antibiotics. More and more studies have shown that Salmonella can be used as a vaccine vector carrying antigens of other pathogens. This has been promising in that the immune system can be elicited in response to both the Salmonella bacteria and the antigen of the pathogen in question. This review aims to highlight some of the milestones attained in the fight against the disease from the time S. typhi was seen as a pathogen causing typhoid fever to the use of Salmonella as a vaccine vector. Cellular & Molecular Immunology. 2008;5(2):91-97.

show abstract

Section: Therapeutic Measures To Salmonella Typhi Infections and Thementioning

confidence: 99%

Salmonella Typhi: from a Human Pathogen to a Vaccine Vector

2008

View full text Add to dashboard Cite

show abstract

“…In agriculture, probiotics/DFM used in animal feed have become accepted as potential alternatives to antibiotics for use as growth-promoters, and in selected cases, for control of specific enteric pathogens (Boyle et al, 2007;Villa et al, 2009). Farm animals are often subjected to environmental stresses, which can cause imbalance in the intestinal ecosystem and this could be a risk factor for pathogenic infections.…”

Section: Agriculturementioning

confidence: 99%

Isolation, Identification and Screening of Potential Probiotic Bacteria in Milk from South African Saanen Goats

Makete

Aiyegoro

Thantsha

2016

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

“…Antibiotic treatment of nontyphoidal salmonellosis is usually indicated for severe infections in children, elderly people, and immunocompromised patients; therapeutic options include folate inhibitors, fluoroquinolones, and oxyiminocephalosporins (2). The development of strains with increasing levels of resistance due to widespread use of antibiotics has been one of the main setbacks for the effective treatment of Salmonella infections (3). Most of the clinical isolates of ␤-lactamase-producing Salmonella synthesize class A ␤-lactamases (4), and the occurrence of isolates carrying plasmidic class C ␤-lactamases has also been reported worldwide (5,6).…”

mentioning

confidence: 99%

Synthesis of Metallo-β-Lactamase VIM-2 Is Associated with a Fitness Reduction in Salmonella enterica Serovar Typhimurium

Cordeiro

Chabalgoity

Yim

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Antibiotic resistance, especially due to ␤-lactamases, has become one of the main obstacles in the correct treatment of Salmonella infections; furthermore, antibiotic resistance determines a gain of function that may encompass a biological cost, or fitness reduction, to the resistant bacteria. The aim of this work was to determine in vitro if the production of the class B ␤-lactamase VIM-2 determined a fitness cost for Salmonella enterica serovar Typhimurium. To that end the gene bla VIM-2 was cloned into the virulent strain S. Typhimurium SL1344, using both the tightly regulated pBAD22 vector and the natural plasmid pST12, for inducible and constitutive expression, respectively. Fitness studies were performed by means of motility, growth rate, invasiveness in epithelial cells, and plasmid stability. The expression of bla VIM-2 was accompanied by alterations in micro-and macroscopic morphology and reduced growth rate and motility, as well as diminished invasiveness in epithelial cells. These results suggest that VIM-2 production entails a substantial fitness cost for S. Typhimurium, which in turn may account for the extremely low number of reports of metallo-␤-lactamase-producing Salmonella spp.

show abstract

Salmonella : from Pathogenesis to Therapeutics

Cited by 131 publications

References 58 publications

Salmonella Typhi: from a Human Pathogen to a Vaccine Vector

Salmonella Typhi: from a Human Pathogen to a Vaccine Vector

Isolation, Identification and Screening of Potential Probiotic Bacteria in Milk from South African Saanen Goats

Synthesis of Metallo-β-Lactamase VIM-2 Is Associated with a Fitness Reduction in Salmonella enterica Serovar Typhimurium

Contact Info

Product

Resources

About